Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)
signaling are established contributors to malignant glioma (MG) biology. We, therefore …

1502 Purpose: To evaluate the efficacy of OSI-774, a small molecule tyrosine kinase
inhibitor of the epidermal growth factor receptor (EGFR), in patients with recurrent malignant …

Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …

Background Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic
target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma …

We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase
inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the …

Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is active in
glioblastoma. We evaluated erlotinib efficacy in patients with first-relapse glioblastoma and …

2005 Background: In 40–50% of GBM epidermal growth factor receptor (EGFR) is amplified,
and often constitutively activated (EGFRvIII mutant). EGFR is therefore a potential …

Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent
anaplastic glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) …

The purpose of this study was to define the maximum tolerated dose of erlotinib and
characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and …

Introduction: The survival of patients with glioblastoma (GBM), which is the most common
primary brain malignancy, remains poor with current treatment modalities. However, an …